Ignite Creation Date:
2024-05-05 @ 11:54 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00169520
Status:
COMPLETED
Last Update Posted:
2008-10-16
First Post:
2005-09-12
Brief Title:
SB-715992 In Combination With Docetaxel In Patients With Solid Tumors
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
A Phase I Open-Label Study of SB-715992 in Combination With Docetaxel in Patients With Advanced Solid Tumors
Status:
COMPLETED
Status Verified Date:
2008-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine the dose regimen of SB-715992 in combination with docetaxel in patients with solid tumors SB-715992 and docetaxel were dosed by 1-hour intravenous infusion every 3 weeks on the same day A patient may continue to receive treatment as long as they are benefiting from the treatment Blood samples will be taken at specific times to measure the amount of both drugs in your body at specific times after the drug is given Blood samples will also be taken for lab tests such as complete blood counts and clinical chemistries Physical exams will be performed before each treatment with SB-715992 During the treatment phase the patients will undergo regular assessments for safety and clinical response
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None